Non-alcoholic fatty liver disease has been reframed in recent years as metabolic dysfunction–associated steatotic liver disease (MASLD) to emphasize its origin in cardio-metabolic dysregulation1. MASLD affects approximately 25% of the global population, with an even higher prevalence rate of 27% in Asia2. Importantly, MASLD is not just a liver problem—it represents a manifestation of the broader metabolic syndrome and carries significant cardiometabolic consequences3. At a recent symposium, Dr. Sollano reviewed the evolving therapeutic landscape in his lecture and highlighted the role of essential phospholipids (EPLs)— especially phosphatidylcholine—as a useful liver-supportive agent in real-world MASLD management, particularly where access to newer treatments remains constrained.

Despite the typically indolent nature of marginal zone lymphoma (MZL), treatment options for patients with relapsed or refractory (R/R) disease have long been limited and largely extrapolated from broader indolent
non-Hodgkin lymphoma studies. Conventional chemoimmunotherapy, though effective, can be poorly tolerated in older or comorbid patients, while first-generation Bruton tyrosine kinase (BTK) inhibitors like ibrutinib have been associated with off-target toxicities. This created a critical therapeutic gap for patients requiring prolonged treatment with manageable safety profiles. Zanubrutinib, a next-generation BTK inhibitor engineered for greater target selectivity and improved tolerability, has emerged as a promising solution. At a recent symposium, Dr. Chandramouli Nagarajan presented the findings of the MAGNOLIA trial, a pivotal phase II study that evaluated Zanubrutinib as monotherapy in patients with R/R MZL. By focusing on a real-world population, including elderly patients, the study offers compelling evidence for the role of Zanubrutinib in reshaping the treatment landscape of MZL.

At a recent webinar, Professor Dan Siskind, Professor of Psychiatry at the University of Queensland, Brisbane, Australia, presented key recommendations from the International College of Neuropsychopharmacology (CINP)-endorsed International Guidelines for the Algorithmic Treatment of Schizophrenia (INTEGRATE).